Modra Pharmaceuticals
Manufacturing · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Barbara Strozzilaan 201, Amsterdam, Nort...Phone Number
+31 205124734Website
www.modrapharmaceuticals.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Modra Pharmaceuticals
Modra Pharmaceuticals is dedicated to improving the lives of cancer patients by transforming taxane therapy through its proprietary boosted oral taxane approach. The company focuses on developing clinical-stage oral formulations of taxanes, such as docetaxel, to enhance delivery, bioavailability, and tolerability, aiming to replace traditional intravenous treatments. Their lead product, ModraDoc006/r, is designed to provide effective cancer treatment with improved safety and convenience, allowing patients to take their medication at home. Modra's innovations seek to reduce the need for hospital visits and minimize side effects, ultimately enhancing the quality of life for cancer patients.Explore more
Modra Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Modra Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Modra Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Modra Pharmaceuticals
Modra Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Modra Pharmaceuticals launches new products
Check out if Modra Pharmaceuticals is spiking on competitors!
Click to see if Modra Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Modra Pharmaceuticals has new funding data
Check if Modra Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Modra Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Modra Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Modra Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Modra Pharmaceuticals.
Modra Pharmaceuticals Tech Stack
A closer look at the technologies used by Modra Pharmaceuticals
See more technologies
Modra Pharmaceuticals News & Media
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced the final results of the lower dose cohort in the Company’s Phase 2b trial evaluating its oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to standard-of-care IV chemotherapy docetaxel at 75 mg/m2 Q3W. ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent which enhances bioavailability. The lowerModra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 – 7, 2022 virtually and in-person in Chicago, IL, USA. Please see below for details on the poster abstract. SesModra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to the standard-of-care, the IV chemotherapy docetaxel. ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent which enhances bioavailability. In a total of 101 patients enrolled, ModraDocModra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board. The new members bring more than 50 years of combined experience in the pharmaceutical and biotechnology industry, and will provide guidance critical for the acceleration of Modra’s growth and business development efforts, as well as the company’s plans for the advancement of lead clinical candidate, ModraDoc006/r, a boost
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Modra Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Modra Pharmaceuticals is dedicated to improving the lives of cancer patients by transforming taxane therapy through its proprietary boosted oral taxane approach. The company focuses on developing clinical-stage oral formulations of taxanes, such as docetaxel, to enhance delivery, bioavailability, and tolerability, aiming to replace traditional intr... Read More
